vTv Therapeutics (VTVT) has received a new Buy rating, initiated by BTIG analyst, Thomas Shrader.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thomas Shrader has given his Buy rating due to a combination of factors surrounding vTv Therapeutics’ lead candidate, cadisegliatin. This drug, designed for type 1 diabetes, is a liver-selective glucokinase activator that has shown promise in improving glucose homeostasis. It holds a Breakthrough Therapy Designation and is currently in a Phase 3 trial, with expectations for the drug to significantly reduce hypoglycemic events.
Cadisegliatin’s potential market impact is substantial, with projected peak sales exceeding $500 million. The drug demonstrated a favorable safety profile in earlier trials, reducing hypoglycemia without increasing the risk of ketoacidosis. The valuation of vTv Therapeutics is supported by a $40 price target, based on a blend of discounted cash flow and peak multiple valuations, reflecting confidence in the company’s future growth and the drug’s commercial viability.
In another report released on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.